Efficacy and Safety of Mavrilimumab in Giant Cell Arteritis A phase II trial in patients with active giant cell arteritis shows that mavrilimumab, a monoclonal antibody against GM-CSF is capable of inducing clinical remission. https://t.co/QmACP1ESFG https://t.co/EeWxTZuFbw